Elisa Pagnin Selected Research

Gitelman Syndrome

8/2018	Gitelman's Syndrome: characterization of a novel c.1181G>A point mutation and functional classification of the known mutations.
12/2015	Assessing the Relationship of Angiotensin II Type 1 Receptors with Erythropoietin in a Human Model of Endogenous Angiotensin II Type 1 Receptor Antagonism.
1/2015	Relationship between NOX4 level and angiotensin II signaling in Gitelman's syndrome. Implications with hypertension.
2/2014	Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients.
7/2012	Calcitonin gene-related peptide, heme oxygenase-1, endothelial progenitor cells and nitric oxide-dependent vasodilation relationships in a human model of angiotensin II type-1 receptor antagonism.
9/2011	Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling.
4/2005	Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome.
8/2004	Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension.
1/2003	Kidney transplant in Gitelman's syndrome. Report of the first case.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elisa Pagnin Research Topics

Disease

15	Hypertension (High Blood Pressure) 06/2021 - 10/2002
9	Gitelman Syndrome 08/2018 - 01/2003
6	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 01/2003
6	Cardiovascular Diseases (Cardiovascular Disease) 06/2014 - 02/2006
4	Hypotension (Low Blood Pressure) 02/2014 - 01/2003
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2021 - 10/2015
3	Fibrosis (Cirrhosis) 01/2016 - 04/2004
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2015 - 02/2011
3	Atherosclerosis 12/2011 - 10/2004
3	Inflammation (Inflammations) 02/2011 - 06/2006
2	Neoplasms (Cancer) 10/2021 - 01/2016
2	Atrial Fibrillation 01/2020 - 01/2019
2	Chronic Renal Insufficiency 01/2019 - 03/2016
2	Fabry Disease (Fabry's Disease) 11/2018 - 01/2018
2	Type 2 Diabetes Mellitus (MODY) 04/2016 - 04/2003
2	Hypertrophy 03/2016 - 06/2014
2	Insulin Resistance 10/2015 - 10/2013
2	Heart Failure 03/2015 - 03/2008
2	Rare Diseases (Rare Disease) 10/2013 - 07/2012
2	Vascular Remodeling 12/2011 - 02/2011
1	Lymphoid Leukemia 10/2021
1	Alkalosis 06/2021
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 11/2018
1	Large Granular Lymphocytic Leukemia 09/2017
1	Neutropenia 09/2017
1	Diabetic Nephropathies (Diabetic Nephropathy) 04/2016
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 03/2016
1	Body Weight (Weight, Body) 10/2015
1	Obesity 10/2015
1	Coronary Disease (Coronary Heart Disease) 03/2015
1	Lung Diseases (Lung Disease) 03/2015
1	Bartter Syndrome (Syndrome, Bartter) 02/2014
1	Wounds and Injuries (Trauma) 09/2010

Drug/Important Bio-Agent (IBA)

12	Angiotensin IIIBA 01/2016 - 01/2003
10	Proteins (Proteins, Gene)FDA Link 01/2016 - 09/2005
9	rho-Associated KinasesIBA 01/2020 - 10/2004
5	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 06/2014 - 04/2003
4	CytokinesIBA 01/2018 - 06/2006
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 10/2002
4	Heme Oxygenase-1IBA 04/2016 - 07/2006
3	EnzymesIBA 11/2018 - 09/2010
3	oxidized low density lipoproteinIBA 06/2014 - 02/2011
3	NADPH Oxidases (NAD(P)H oxidase)IBA 09/2008 - 04/2003
2	Vitamin E FDA LinkGeneric 01/2019 - 02/2011
2	Glucose (Dextrose)FDA LinkGeneric 10/2015 - 09/2010
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2015 - 02/2006
2	LDL CholesterolIBA 03/2015 - 02/2006
2	Messenger RNA (mRNA)IBA 02/2014 - 09/2005
2	Type 1 Angiotensin ReceptorIBA 02/2014 - 10/2013
2	AntioxidantsIBA 01/2014 - 12/2011
2	Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA 01/2014 - 02/2011
2	erucylphosphocholineIBA 07/2012 - 09/2011
2	GTP-Binding Proteins (G-Protein)IBA 05/2008 - 08/2004
2	C-Reactive ProteinIBA 06/2006 - 04/2006
2	Superoxides (Superoxide)IBA 03/2005 - 04/2003
2	AldosteroneIBA 04/2004 - 01/2003
1	ibrutinibIBA 10/2021
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 10/2021
1	Transcription Factors (Transcription Factor)IBA 10/2021
1	SodiumIBA 06/2021
1	Gap Junction alpha-5 ProteinIBA 01/2020
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 10/2019
1	HDL LipoproteinsIBA 01/2019
1	GalactosidasesIBA 11/2018
1	globotriaosylceramide (globotriosylceramide)IBA 11/2018
1	SymportersIBA 08/2018
1	Sodium Chloride FDA LinkGeneric 08/2018
1	Fas Ligand Protein (Fas Ligand)IBA 09/2017
1	Biological ProductsIBA 09/2017
1	Pharmaceutical PreparationsIBA 01/2016
1	Cadherins (E-Cadherin)IBA 01/2016
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2016
1	Endothelin-1 (Endothelin 1)IBA 01/2016
1	NADPH Oxidase 4IBA 12/2015
1	Oxygen (Dioxygen)IBA 12/2015
1	Insulin (Novolin)FDA Link 10/2015
1	LeptinIBA 10/2015
1	HDL CholesterolIBA 03/2015
1	LipidsIBA 03/2015
1	AdipokinesIBA 06/2014
1	Capsules (Microcapsules)IBA 06/2014
1	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 06/2014
1	Calcitonin Gene-Related PeptideIBA 01/2014
1	Sirtuin 1IBA 10/2013
1	AngiotensinsIBA 07/2012
1	Angiotensin II Type 1 Receptor BlockersIBA 12/2011
1	LDL Lipoproteins (beta Lipoproteins)IBA 12/2011
1	olmesartanIBA 12/2011
1	Bicarbonates (Hydrogen Carbonate)IBA 02/2011
1	Plasminogen InactivatorsIBA 02/2011
1	TOR Serine-Threonine KinasesIBA 02/2011
1	ImmunosorbentsIBA 02/2011
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2011
1	Nitric Oxide Synthase (NO Synthase)IBA 02/2011
1	beta CateninIBA 09/2010

Therapy/Procedure

2	Renal Dialysis (Hemodialysis) 01/2019 - 02/2011
2	Therapeutics 03/2016 - 09/2015
1	Enzyme Replacement Therapy 01/2018
1	Time-to-Treatment 10/2015
1	Hemodiafiltration 02/2011